RNAI-MEDIATED SILENCING OF MATRIX METALLOPROTEINASE 1 IN EPIDERMAL KERATINOCYTES INFLUENCES THE BIOLOGICAL EFFECTS OF INTERLEUKIN 17A

Matrix metalloproteinases (MMPs) are important for the pathogenesis of psoriasis and other autoimmune disorders. In the extracellular matrix, accumulation of proinflammatory cytokines, such as interleukin 17A (IL-17A), leads to induction of several MMPs, including MMP1. MMPs change the composition and other properties of the extracellular matrix. These changes facilitate tissue remodeling and promote the development of psoriatic plaques. The aim of this study was to explore how MMP1 silencing might influence the biological effects of IL-17A on migration and proliferation of human epidermal keratinocytes and the expression of genes involved in their division and differentiation. The experiments were performed with MMP1-deficient and control epidermal keratinocytes, HaCaT-MMP1 and HaCaT-KTR, respectively. Cell proliferation and migration were assessed by comparative analysis of the growth curves and scratch assay, respectively. To quantify cell migration, representative areas of cell cultures were photographed at the indicated time points and compared to each other. Changes in gene expression were analyzed by real-time PCR. The obtained results demonstrated that MMP1 silencing in the cells treated with IL-17A resulted in downregulation of MMP9 and -12, FOSL1, CCNA2, IVL, KRT14 and -17 as well as upregulation of MMP2, CCND1 and LOR. Moreover, MMP1 silencing led to a decrease in cell proliferation and an impairment of cell migration. Thus, MMP1-deficiency in epidermal keratinocytes can be beneficial for psoriasis patients that experience an accumulation of IL-17 in lesional skin. Knocking MMP1 down could influence migration and proliferation of epidermal keratinocytes in vivo, as well as help to control the expression of MMP1, -2, -9 и -12, CCNA2, CCND1, KRT14 and -17 that are crucial for the pathogenesis of psoriasis.

1. Al Robaee A.A. Molecular genetics of Psoriasis (Principles, technology, gene location, genetic polymorphism and gene expression). Int. J. Health Sci. (Qassim). 2010;4(2):103-127.

2. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., Viswanathan A., Holder G.E., Stockman A., Tyler N., Petersen-Jones S., Bhattacharya S.S., Thrasher A.J., Fitzke F.W., Carter B.J., Rubin G.S., Moore A.T., Ali R.R. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N. Engl. J. Med. 2008;358(21):2231-2239. DOI 10.1056/NEJMoa0802268.

3. Batyrshina S.V., Sadykova F.G. Comorbid conditions in patients with psoriasis. Prakticheskaya Meditsina = Practical Medicine. 2014;8:32-35. (in Russian)

4. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303-313. DOI 10.1016/j.cell.2004.12.018.

5. Canavan T.N., Elmets C.A., Cantrell W.L., Evans J.M., Elewski B.E. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am. J. Clin. Dermatol. 2016;17(1):33-47. DOI 10.1007/s40257-015-0162-4.

6. Cho K.A., Suh J.W., Lee K.H., Kang J.L., Woo S.Y. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 2012;24(3):147-158. DOI 10.1093/intimm/dxr110.

7. Chomczynski P., Mackey K. Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide and proteoglycan-rich sources. BioTechniques. 1995;19(6):942-945.

8. Goldminz A.M., Elder J.T., Lebwohl M.G., Gladman D.D., Wu J.J., Mehta N.N., Finlay A.Y., Gottlieb A.B. Psoriasis. Nat. Rev. Dis. Primers. 2016;2:16082. DOI 10.1038/nrdp.2016.82.

9. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., Thrasher A.J., Wulffraat N., Sorensen R., Dupuis-Girod S., Fischer A., Davies E.G., Kuis W., Leiva L., Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 2002;346(16): 1185-1193. DOI 10.1056/NEJMoa012616.

10. Jakobsen M., Stenderup K., Rosada C., Moldt B., Kamp S., Dam T.N., Jensen T.G., Mikkelsen J.G. Amelioration of psoriasis by anti-TNF-α RNAi in the xenograft transplantation model. Mol. Ther. 2009;17(10):1743-1753. DOI 10.1038/mt.2009.141.

11. Jin L., Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis. Med. Res. Rev. 2014;34(2):438-454. DOI 10.1002/med.21291.

12. Khamaganova I.V., Almazova A.A., Lebedeva G.A., Ermachenko A.V. Psoriasis epidemiology issues. Klinicheskaya Dermatologiya i Ve nerologiya = Russian Journal of Dermatology and Venereo logy. 2015;1:12-16. DOI 10.17116/klinderma2015112-16. (in Russian)

13. Korotaeva T.V. Prospects for using interleukin-17 inhibitors, a new class of drugs for targeted therapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):346-351. DOI 10.14412/1995-4484-2016346-351. (in Russian)

14. Ma W.Y., Jia K., Zhang Y. IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα. Exp. Ther. Med. 2016;11(2):631-636. DOI 10.3892/etm.2015.2939.

15. Manczinger M., Kemény L. Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach. PLoS One. 2013;8(11):e80751. DOI 10.1371/journal.pone.0080751.

16. Matsushime H., Ewen M.E., Strom D.K., Kato J.Y., Hanks S.K., Roussel M.F., Sherr C.J. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 1992;71(2):323-334.

17. Mezentsev A., Nikolaev A., Bruskin S. Matrix metalloproteinases and their role in psoriasis. Gene. 2014;540(1):1-10. DOI 10.1016/j.gene.2014.01.068.

18. Michalek I.M., Loring B., John S.M. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venerol. 2017; 31(2):205-212. DOI 10.1111/jdv.13854.

19. Mills K.H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 2008;38(10):2636-2649. DOI 10.1002/eji.200838535.

20. Mishina O.S., Dvornikov A.S., Dontsova E.V. Psoriasis and psoriatic arthritis: Analysis of 2009–2011 incidence rates in the Russian Federation. Doctor.ru. 2013;4:52-55. (in Russian)

21. Mogulevtseva J.A., Mezentsev A.V. Optimization of lentiviral transduction of immortalized epidermal keratinocytes. Modern Science: Theory and Practice. 2017;13:123-134. (in Russian)

22. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., Gudjonsson J.E., Li Y., Tejasvi T., Feng B.J., Ruether A., Schreiber S., Weichenthal M., Gladman D., Rahman P., Schrodi S.J., Prahalad S., Guthery S.L., Fischer J., Liao W., Kwok P.Y., Menter A., Lathrop G.M., Wise C.A., Begovich A.B., Voorhees J.J., Elder J.T., Krueger G.G., Bowcock A.M., Abecasis G.R., for the Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 2009; 41(2):199-204. DOI 10.1038/ng.311.

23. NCBI Probe. 2015. Available at https://www.ncbi.nlm.nih.gov/probe/

24. Noh M., Yeo H., Ko J., Kim H.K., Lee C.H. MAP17 is associated with the T-helper cell cytokine-induced down-regulation of filaggrin transcription in human keratinocytes. Exp. Dermatol. 2010;19(4):355-362. DOI 10.1111/j.1600-0625.2009.00902.x.

25. Pagano M., Pepperkok R., Verde F., Ansorge W., Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992; 11(3):961-971.

26. Peric M., Koglin S., Dombrowski Y., Gross K., Bradac E., Büchau A., Steinmeyer A., Zügel U., Ruzicka T., Schauber J. Vitamin D analogs differentially control antimicrobial peptide/“alarmin” expression in psoriasis. PLoS One. 2009;4(7):e6340. DOI 10.1371/journal.pone.0006340.

27. Peric M., Koglin S., Kim S.M., Morizane S., Besch R., Prinz J.C., Ruzicka T., Gallo R.L., Schauber J. IL-17A enhances vitamin D3induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J. Immunol. 2008;181(12):8504-8512.

28. Rao K.S., Babu K.K., Gupta P.D. Keratins and skin disorders. Cell. Biol. Int. 1996;20(4):261-274.

29. Reischl J., Schwenke S., Beekman J.M., Mrowietz U., Stürzebecher S., Heubach J.F. Increased expression of Wnt5a in psoriatic plaques. J. Invest. Dermatol. 2007;127(1):163-169. DOI 10.1038/sj.jid.5700488.

30. Rukavishnikova V.M. Change of nails at psoriasis. Vestnik Dermatologii i Venerologii = Bulletin of Dermatology and Venereology. 2009;2:71-79. (in Russian)

31. Schindelin J., Rueden C.T., Hiner M.C., Eliceiri K.W. The ImageJ ecosystem: An open platform for biomedical image analysis. Mol. Reprod. Dev. 2015;82(7-8):518-529. DOI 10.1002/mrd.22489.

32. Scott K.A., Arnott C.H., Robinson S.C., Moore R.J., Thompson R.G., Marshall J.F., Balkwill F.R. TNF-α regulates epithelial expression of MMP-9 and integrin αvβ6 during tumour promotion. A role for TNF-α in keratinocyte migration? Oncogene. 2004;23(41):69546966. DOI 10.1038/sj.onc.1207915.

33. Seo K.Y., Kitamura K., Han S.J., Kelsall B. Th17 cells mediate inflammation in a novel model of spontaneous experimental autoimmune lacrimal keratoconjunctivitis with neural damage. J. Allergy Clin. Immunol. 2017; pii: S0091-6749(17)31504-X. DOI 10.1016/j.jaci. 2017.07.052.

34. Seo M.D., Kang T.J., Lee C.H., Lee A.Y., Noh M. HaCaT keratinocytes and primary epidermal keratinocytes have different transcriptional profiles of cornified envelope-associated genes to T helper cell cytokines. Biomol. Ther. (Seoul). 2012;20(2):171176. DOI 10.4062/biomolther.2012.20.2.171.

35. Shilova L.N., Pan’shina N.N., Chernov A.S., Trubenko Y.A., Khortieva S.S., Morozova T.A., Pan’shin N.G. Immunopathological significance of interleukin-17 in psoriatic arthritis. Sovremennye Problemy Nauki i Obrazovaniya = Current Problems of Science and Education. 2015;6:54. (in Russian)

36. Sobolev V.V., Starodubtseva N.L., Soboleva A.G., Rakhimova O.Yu., Korsunskaya I.M., Piruzian E.S., Minnibaev M.T., Krivoschapov L., Bruskin S.A., Voron’ko O.E. Role of interleukins in psoriasis. Sovremennye Problemy Dermatovenerologii, Immunologii i Vrachebnoy Kosmetologii = Current Problems of Dermatovenerology, Immunology, and Medical Cosmetology. 2010;5(5):79-84. (in Russian)

37. Soboleva A.G., Mezentsev A., Zolotorenko A., Bruskin S., Pirusian E. Three-dimensional skin models of psoriasis. Cells Tissues Organs. 2014a;199(5-6):301-310. DOI 10.1159/000369925.

38. Soboleva A.G., Zolotarenko A.D., Sobolev V.V., Bruskin S.A., Piruzian E.S., Mezentsev A.V. Genetically predetermined limitation in HaCaT cells that affects their ability to serve as an experimental model of psoriasis. Russ. J. Genetics (Moscow). 2014b;50(10):1081-1089. DOI 10.1134/S1022795414100123.

39. Starodub tseva N.L., So bo lev V.V., Soboleva A.G., Nikolaev A.A., Bruskin S.A. Genes expression of metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis. Russ. J. Genetics (Moscow). 2011;47(9):1117-1123. DOI 10.1134/S102279541109016X.

40. Tohyama M., Hanakawa Y., Shirakata Y., Dai X., Yang L., Hirakawa S., Tokumaru S., Okazaki H., Sayama K., Hashimoto K. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur. J. Immunol. 2009;39(10):27792788. DOI 10.1002/eji.200939473.

41. Vegfors J., Ekman A.K., Stoll S.W., Bivik Eding C., Enerbäck C. Psoriasin (S100A7) promotes stress-induced angiogenesis. Br. J. Dermatol. 2016;175(6):1263-1273. DOI 10.1111/bjd.14718.

42. Wells J.M., Gaggar A., Blalock J.E. MMP generated matrikines. Matrix Biol. 2015;44-46:122-129. DOI 10.1016/j.matbio.2015.01.016.

43. Wu Y., Zhu L., Liu L., Zhang J., Peng B. Interleukin-17A stimulates migration of periodontal ligament fibroblasts via p38 MAPK/NF-κB-dependent MMP-1 expression. J. Cell. Physiol. 2014;229(3):292-299. DOI 10.1002/jcp.24444.

44. Yazici A.C., Tursen U., Apa D.D., Ikizoglu G., Api H., Baz K., Tasdelen B. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch. Dermatol. Res. 2005;297(6):249-255. DOI 10.1007/s00403-005-0602-8.

45. Zolotarenko A., Chekalin E., Mesentsev A., Kiseleva L., Gribanova E., Mehta R., Baranova A., Tatarinova T.V., Piruzian E.S., Bruskin S. Integrated computational approach to the analysis of RNA-seq data reveals new transcriptional regulators of psoriasis. Exp. Mol. Med. 2016;48(11):e268. DOI 10.1038/emm.2016.97.